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 We found a late presented congenital myasthenic syndrome (CMS) patient with 
novel CHRNE gene mutations. Although our patient has shown blepharoptosis since 
youth, fatigable muscle weakness began at age 71. Genetic analysis revealed novel 
compound heterozygous CHRNE mutations (c.1032+2 T>G, c.1306_1307 delGA). His 
myasthenic symptoms were well managed by oral anti-cholinesterase drug until he died 
at 82-year old. The present case showed mild myasthenic symptoms with very late 
presentation and slow progression. Late presented CMS is often underdiagnosed, 
therefore, genetic testing is important to distinguish it from other myasthenic disease. 
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 Congenital myasthenic syndrome (CMS) is characterized by easy fatigability of 
skeletal muscle due to genetic disorders relating to neuromuscular transmission [1].  
CMS is a heterogeneous disorder due to different gene mutations [1, 2]. Although 9.2 per 
million children under the age of 18 have been genetically diagnosed in the UK, the exact 
prevalence of CMS worldwide is uncertain [2, 3].  
 
Case presentation 
 The proband (71-year old male, II-9) became aware of muscle weakness in his 
bilateral upper extremities. At 76-year old, he came to feel physical fatigue with gradual 
progression of muscle weakness. A few months later, he developed bilateral 
blepharoptosis and double vision, and was admitted to our hospital. 
  His neurological examination revealed bilateral blepharoptosis with easy 
fatigability, exotropia in his right eye, restriction of bilateral eye movement in all 
directions, mild facial muscle weakness, slight muscle atrophy and weakness in all 
extremities with proximal dominancy, normoreflexia, and normal gait. The pedigree (Fig. 
1A) suggested an autosomal recessive inheritance and his portraits showed that the 
bilateral blepharoptosis was already present at age 19 with progression in the course of 
age (Fig. 1B, i=19, ii=45, iii=76, iv=80-year old).  
Both AChR antibodies and muscle specific kinase (MuSK) antibodies were 
negative. Edrophonium test showed improvement in the elevation of eyelids (Fig. 1C-i), 
eye movements (Fig. 1C-ii, iii, iv), and left arm strength (Fig. 1C-v, arrow). Repetitive 
nerve stimulation (RNS) at 3 Hz showed waning both on left ulnar (Fig. 1D-i) and left 
facial (Fig. 1D-ii) nerve analyses (13.5% and 27.2%, respectively). His left arm muscle 
biopsy showed only pyknotic nuclear clumps (Fig. 1E-i, arrow). The cytochrome c 
oxidase (COX) activity did not decrease (Fig. 1E-iv), and there was no ragged-red fiber. 
 The whole exome DNA analysis was performed with written informed consent, 
and heterozygote mutations were identified for a single nucleotide substitution (c.1032+2 
T>G) and a 2 bp deletion (c.1306_1307 delGA) of the CHRNE gene. These mutations 
were then confirmed by the Sanger direct sequencing method (Fig. 1F). The single 
nucleotide substitution (c.1032+2 T>G) was further confirmed by polymerase chain 
reaction-restriction fragment length polymorphism (PCR-RFLP) (Fig. G-i). The 2 bp 
deletion (c.1306_1307 delGA) was also confirmed by allele specific PCR (AS-PCR) (Fig. 
1G-ii).  
Reverse transcription (RT)-PCR was performed on RNA samples extracted from 
the patient’s muscle specimen, then two different size of PCR products were obtained by 
using primers recognizing the region including exon 8-11 in the CHRNE gene (Fig. 1H). 
As a result of sequence analysis of purified DNA from each PCR product, band 1 of 
470bp showed a sequence of exon 8-11 with a mutation of c.1306_1307 delGA in exon 
11 (Fig. 1I-i). Band 2 of 355bp showed the sequence skipping exon 9 without a mutation 
of c.1306_1307 delGA in exon 11 (Fig. 1I-ii). These results suggested compound 
heterozygous CHRNE mutations. Oral anti-cholinesterase (ChE) drug was administered 
from his age 80 and well managed myasthenic symptoms until he died at 82. 
 
Discussion 
CMS usually shows myasthenic symptoms in neonate or early childhood, but 
much less in late childhood. Therefore, adult onset CMS may often be mistaken for 
SNMG, myopathy, or motor neuron disease [1, 4, 5]. Our present case was initially 
difficult to distinguish from SNMG because of the very late presentation of symptoms at 
age 71. 
Because the first and last two bases of intron (GT and AG motives) are preserved 
across the species as a splice site, genetic mutations of them could result in a splicing 
defect such as exon skipping or intron retention [6]. In the present case, one novel 
mutation of the CHRNE gene is a point mutation at the 5’ splice site of intron 9, which 
causes frameshift by skipping exon 9 (115 bp) with premature termination. Another novel 
mutation is 2 bp deletion, which results in a stop codon at the 454th amino acid. Because 
a stop codon is translocated in the last exon 12, nonsense-mediated mRNA decay (NMD) 
may not be induced in our case [7]. On the other hand, the downstream 470th cysteine 
residue (C470) is essential for surface expression of adult AChR [8]. Therefore, this 
mutation is also considered to be associated with AChR deficiency.  
Our case showed mild myasthenic symptoms with very late presentation, 
probably because low level expression of the fetal AChR harboring γ subunit can partially 
compensate for the AChR deficiency [9]. Although adult onset type is often observed in 
autosomal dominant slow channel syndrome [1, 10, 11], clinical manifestations in our 
case suggested fast channel syndrome or post-synaptic AChR deficiency type. 
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Fig. 1. (A) The family tree of the patient, showing the proband (II-9, arrow) and his elder 
brother (II-5) with blepharoptosis.  (B) The chronological changes of blepharoptosis 
showing early onset and slow progression at ages of 19 (i), 45 (ii), 76 (iii), and 80 (iv).  
(C) Edrophonium test showed improvements of ptosis (i), eye movements (ii-iv), and left 
arm power (v, arrow).  (D) Repetitive nerve stimulation (RNS) at 3Hz, showing a 
waning in the left ulnar (i) and left facial (ii) nerves.  (E) Histopathological findings of 
his left arm muscle biopsy demonstrated (i) only pyknotic nuclear clumps in Hematoxylin 
and Eosin staining, (ii) no ragged red fiber in Modified Gomori trichrome staining, (iii) 
no fiber type grouping in NADH-tetrazolium reductase (NADH-TR) staining, and (iv) no 
decrease of COX activity in cytochrome c oxidase (COX) staining.  (F) DNA 
sequencing revealed a single nucleotide substitution (c.1032+2 T>G, i, arrow) and a 2 bp 
deletion (c.1306_1307 delGA) in the CHRNE gene (ii, arrowheads).  (G) The single 
nucleotide substitution (c.1032+2 T>G) was confirmed by polymerase chain reaction 
restriction fragment length polymorphism (PCR-RFLP) with uncut PCR product band 
(752 bp) in the patient (i).  The 2 bp deletion (c1306_1307 delGA) was confirmed by 
allele specific PCR (AS-PCR) showing a band of PCR products amplified with AS primer 
for variant only in the patient (ii).  (H) Reverse transcription (RT)-PCR on RNA from 
the patient’s muscle using flanking primers for exon 8 and exon 11 in the CHRNE gene 
showed different two bands (band 1 of 470bp, and band 2 of 355bp).  (I) The DNA 
sequence of band 1 showed a chain of exon 8-11 with a mutation of c.1306_1307 delGA 
in exon 11 (i). The sequence of band 2 showed skipping exon 9 without a mutation of 
c.1306_1307 delGA (ii).  (J) The DNA sequence of each RT-PCR product showed 
compound heterozygous CHRNE mutations. 
